Cargando…

Current therapy and development of therapeutic agents for lung cancer

In the past decades, great progress has been made for the prevention and treatment of lung cancer. Yet, lung cancer remains as the leading cause of cancer death worldwide. In this manuscript, we describe the current genetic and molecular characterization of lung cancer subtypes, review up-to-date tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zilai, Kim, Jiyeon, Zhang, Pin, Galvan Achi, Jazmin M., Jiang, Yuwei, Rong, Lijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120308/
https://www.ncbi.nlm.nih.gov/pubmed/37193130
http://dx.doi.org/10.1016/j.cellin.2022.100015
_version_ 1785029164763447296
author Wang, Zilai
Kim, Jiyeon
Zhang, Pin
Galvan Achi, Jazmin M.
Jiang, Yuwei
Rong, Lijun
author_facet Wang, Zilai
Kim, Jiyeon
Zhang, Pin
Galvan Achi, Jazmin M.
Jiang, Yuwei
Rong, Lijun
author_sort Wang, Zilai
collection PubMed
description In the past decades, great progress has been made for the prevention and treatment of lung cancer. Yet, lung cancer remains as the leading cause of cancer death worldwide. In this manuscript, we describe the current genetic and molecular characterization of lung cancer subtypes, review up-to-date treatment options for lung cancer patients, summarize the antibodies and small molecule drugs under clinical development, and elaborate on the expression and characteristics of important RTK primary targets and representative preclinical agents which may provide new opportunities for lung cancer treatment. Since gefitinib was first introduced to non-small-cell lung carcinoma (NSCLC) patients in 2002, remarkable progress has been made in targeted therapy for NSCLC patients with the development of multiple generations of small molecule inhibitors targeting relevant driver mutations. However, very little achievement has been made in the development of targeted drugs for small-cell lung carcinoma (SCLC). The successful harness of immune checkpoint inhibitors against PD-1/PD-L1 has marked a major advancement in recent lung cancer treatment. Looking forward, therapeutic strategies that tackle brain metastasis are highly desirable, the combination of molecular testing and strategies tailored to tackle tumor heterogeneity and resistance mechanisms is the key direction for future development.
format Online
Article
Text
id pubmed-10120308
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-101203082023-05-15 Current therapy and development of therapeutic agents for lung cancer Wang, Zilai Kim, Jiyeon Zhang, Pin Galvan Achi, Jazmin M. Jiang, Yuwei Rong, Lijun Cell Insight Review In the past decades, great progress has been made for the prevention and treatment of lung cancer. Yet, lung cancer remains as the leading cause of cancer death worldwide. In this manuscript, we describe the current genetic and molecular characterization of lung cancer subtypes, review up-to-date treatment options for lung cancer patients, summarize the antibodies and small molecule drugs under clinical development, and elaborate on the expression and characteristics of important RTK primary targets and representative preclinical agents which may provide new opportunities for lung cancer treatment. Since gefitinib was first introduced to non-small-cell lung carcinoma (NSCLC) patients in 2002, remarkable progress has been made in targeted therapy for NSCLC patients with the development of multiple generations of small molecule inhibitors targeting relevant driver mutations. However, very little achievement has been made in the development of targeted drugs for small-cell lung carcinoma (SCLC). The successful harness of immune checkpoint inhibitors against PD-1/PD-L1 has marked a major advancement in recent lung cancer treatment. Looking forward, therapeutic strategies that tackle brain metastasis are highly desirable, the combination of molecular testing and strategies tailored to tackle tumor heterogeneity and resistance mechanisms is the key direction for future development. Elsevier 2022-02-09 /pmc/articles/PMC10120308/ /pubmed/37193130 http://dx.doi.org/10.1016/j.cellin.2022.100015 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Wang, Zilai
Kim, Jiyeon
Zhang, Pin
Galvan Achi, Jazmin M.
Jiang, Yuwei
Rong, Lijun
Current therapy and development of therapeutic agents for lung cancer
title Current therapy and development of therapeutic agents for lung cancer
title_full Current therapy and development of therapeutic agents for lung cancer
title_fullStr Current therapy and development of therapeutic agents for lung cancer
title_full_unstemmed Current therapy and development of therapeutic agents for lung cancer
title_short Current therapy and development of therapeutic agents for lung cancer
title_sort current therapy and development of therapeutic agents for lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120308/
https://www.ncbi.nlm.nih.gov/pubmed/37193130
http://dx.doi.org/10.1016/j.cellin.2022.100015
work_keys_str_mv AT wangzilai currenttherapyanddevelopmentoftherapeuticagentsforlungcancer
AT kimjiyeon currenttherapyanddevelopmentoftherapeuticagentsforlungcancer
AT zhangpin currenttherapyanddevelopmentoftherapeuticagentsforlungcancer
AT galvanachijazminm currenttherapyanddevelopmentoftherapeuticagentsforlungcancer
AT jiangyuwei currenttherapyanddevelopmentoftherapeuticagentsforlungcancer
AT ronglijun currenttherapyanddevelopmentoftherapeuticagentsforlungcancer